NCT02310464: Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects

NCT02310464
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 21 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Breast cancer patients are not eligible for cohort expansion phase
Exclusions: No known central nervous system (CNS) metastases
https://ClinicalTrials.gov/show/NCT02310464

Comments are closed.

Up ↑